BACKGROUND: Current guidelines favor transabdominal radical resection (RR) over transanal local excision (TAX) followed by adjuvant therapy (TAXa) for pT1N0 rectal tumors with high-risk features. Comparison of oncologic outcomes between these approaches is limited, although the former is associated with increased postoperative morbidity. We hypothesize that such treatment strategies result in equivalent long-term survival. METHODS: A retrospective cohort study was conducted using the National Cancer Database (2010-2016) to identify patients with pT1N0 rectal adenocarcinoma with high-risk features who underwent TAX or RR for curative intent. The primary outcome was 5-year overall survival (OS), evaluated with log-rank and Cox-proportional hazards testing. RESULTS: A total of 1159 patients (age 67.4 ± 12.9 years; 56.6% male; 83.3% White) met study criteria, of which 1009 (87.1%) underwent RR and 150 (12.9%) underwent TAXa. Patients undergoing TAXa had shorter lengths of stay (RR = 6.5 days, TAXa = 2.7 days, p < 0.001). The 5-year OS was equivalent between groups. TAX without adjuvant therapy was associated with an increased risk of mortality (hazard ratio 1.81, 95% confidence interval 1.17-2.78, p = 0.01). CONCLUSIONS: This is the largest study to demonstrate equivalent 5-year OS between TAXa and RR for T1N0 rectal cancer with high-risk features. These findings may guide the development of prospective, randomized trials and influence changes in practice recommendations for early-stage rectal cancer.
BACKGROUND: Current guidelines favor transabdominal radical resection (RR) over transanal local excision (TAX) followed by adjuvant therapy (TAXa) for pT1N0 rectal tumors with high-risk features. Comparison of oncologic outcomes between these approaches is limited, although the former is associated with increased postoperative morbidity. We hypothesize that such treatment strategies result in equivalent long-term survival. METHODS: A retrospective cohort study was conducted using the National Cancer Database (2010-2016) to identify patients with pT1N0 rectal adenocarcinoma with high-risk features who underwent TAX or RR for curative intent. The primary outcome was 5-year overall survival (OS), evaluated with log-rank and Cox-proportional hazards testing. RESULTS: A total of 1159 patients (age 67.4 ± 12.9 years; 56.6% male; 83.3% White) met study criteria, of which 1009 (87.1%) underwent RR and 150 (12.9%) underwent TAXa. Patients undergoing TAXa had shorter lengths of stay (RR = 6.5 days, TAXa = 2.7 days, p < 0.001). The 5-year OS was equivalent between groups. TAX without adjuvant therapy was associated with an increased risk of mortality (hazard ratio 1.81, 95% confidence interval 1.17-2.78, p = 0.01). CONCLUSIONS: This is the largest study to demonstrate equivalent 5-year OS between TAXa and RR for T1N0 rectal cancer with high-risk features. These findings may guide the development of prospective, randomized trials and influence changes in practice recommendations for early-stage rectal cancer.
Authors: C A M Marijnen; I D Nagtegaal; E Kapiteijn; E Klein Kranenbarg; E M Noordijk; J H J M van Krieken; C J H van de Velde; J W H Leer Journal: Int J Radiat Oncol Biol Phys Date: 2003-04-01 Impact factor: 7.038
Authors: S Balyasnikova; J Read; D Tait; A Wotherspoon; I Swift; D Cunningham; P Tekkis; G Brown Journal: Colorectal Dis Date: 2017-02 Impact factor: 3.788
Authors: W A A Borstlap; T J Coeymans; P J Tanis; C A M Marijnen; C Cunningham; W A Bemelman; J B Tuynman Journal: Br J Surg Date: 2016-06-15 Impact factor: 6.939
Authors: P Terry Phang; John K MacFarlane; Robert H Taylor; Rona E Cheifetz; Noelle Davis; John H Hay; Greg McGregor; Caroline Speers; Barry J Sullivan; Janet Pitts; Andrew J Coldman Journal: Am J Surg Date: 2002-05 Impact factor: 2.565
Authors: Garrett M Nash; Martin R Weiser; José G Guillem; Larissa K Temple; Jinru Shia; Mithat Gonen; W Douglas Wong; Philip B Paty Journal: Dis Colon Rectum Date: 2009-04 Impact factor: 4.585
Authors: S P Bach; J Hill; J R T Monson; J N L Simson; L Lane; A Merrie; B Warren; N J McC Mortensen Journal: Br J Surg Date: 2009-03 Impact factor: 6.939